FDA Approves Emcitate for MCT8 Deficiency Treatment

By Daniel Mercer Charlotte, NC · HEALTH DESK

Published Updated 3 min read

The FDA approved Emcitate on September 28, 2026, to treat peripheral thyrotoxicosis in patients with MCT8 deficiency. The drug will be commercially available in the U.S. within eight to ten weeks.

Emcitate is approved to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. Peripheral thyrotoxicosis involves excess thyroid hormone levels in the blood, which can cause rapid heart rate, increased blood pressure, and adverse effects on metabolism.

The active ingredient in Emcitate is tiratricol, which can enter cells without relying on the MCT8 transporter. The therapy bypasses the broken transporter responsible for MCT8 deficiency to decrease elevated blood thyroid hormone levels.

The effectiveness of Emcitate was evaluated in studies ranging from infants to adults. These studies showed that Emcitate reduces excess thyroid hormone levels. Common side effects of the medication include diarrhea, vomiting, rash, and excessive sweating.

Emcitate was granted Orphan Drug, Rare Pediatric Disease, Fast Track, and Breakthrough Therapy designations. Egetis Therapeutics has a history of receiving these designations for Emcitate in the U.S. The company was previously involved in the development of a drug for Resistance to Thyroid Hormone Beta (RTHβ), which received Orphan Drug Designation in both the EU and the U.S.

The median life expectancy for patients with MCT8 deficiency is approximately 35 years, according to data provided by Egetis. In the U.S., Emcitate is expected to be commercially available within eight to ten weeks post-approval. Egetis is launching its Egetis RareLink patient support program in partnership with PANTHERx Rare to ensure access for patients and caregivers.

The FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval of Emcitate. The company plans to monetize the voucher, potentially in the fourth quarter of 2026, subject to market conditions.

Why It Matters

The approval addresses a severe condition where patients have a median life expectancy of approximately 35 years. By providing the first FDA-approved treatment option, the agency has authorized a therapy that targets the underlying mechanism of excess thyroid hormone accumulation in patients who previously had no regulatory-cleared intervention.

Egetis Therapeutics AB received EU approval for Emcitate in February 2025, making it the first treatment for MCT8 deficiency in the EU. This prior authorization served as a precedent for its subsequent FDA approval in the U.S. The company plans to explore monetizing the associated Priority Review Voucher in Q4 2026.

Timeline

The U.S. Food and Drug Administration approved Emcitate (tiratricol) tablets for oral suspension on September 28, 2026. On that same date, the agency confirmed that Emcitate is approved to treat peripheral thyrotoxicosis in patients with MCT8 deficiency and is the first therapy approved by the FDA to treat symptoms of MCT8 deficiency. The approval was granted to Egetis Therapeutics US Inc.

What's New

Later reporting indicates that in 2025, the European Commission approved Emcitate® (tiratricol) as the first and only treatment for MCT8 deficiency in the EU, with a launch in Germany on May 1, 2025, setting a precedent for its subsequent FDA approval in the U.S. Additional details show the FDA's approval of Emcitate came after the completion of multiple clinical trials, including the ReTRIACt study, which demonstrated that tiratricol could significantly suppress serum T3 levels in patients with MCT8 deficiency, with effects sustained over up to 3.5 years.

Further information reveals the FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) granted to Egetis in connection with Emcitate’s approval could potentially be monetized, with the company planning to explore this in Q4 2026. The FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval of Emcitate, which the company plans to monetize, potentially in the fourth quarter of 2026, subject to market conditions. Data provided by Egetis shows that the median life expectancy for patients with MCT8 deficiency is approximately 35 years, reflecting the severity of the condition and the significance of the FDA’s approval of Emcitate.

Egetis Therapeutics AB (parent company) received EU approval for Emcitate in February 2025, making it the first treatment for MCT8 deficiency in the EU, which served as a precedent for its subsequent FDA approval in the U.S. Egetis Therapeutics has a history of receiving Orphan Drug, Fast Track, and Breakthrough Therapy designations for Emcitate in the U.S., reflecting its focus on addressing rare pediatric conditions with significant unmet medical needs. In the U.S., Emcitate is expected to be commercially available within eight to ten weeks post-approval, with Egetis launching its Egetis RareLink™ patient support program in partnership with PANTHERx® Rare to ensure access for patients and caregivers.

fact_check Facts

The U.S. Food and Drug Administration approved Emcitate (tiratricol) tablets for oral suspension on September 28, 2026.
Source: fda.gov
Emcitate is approved to treat peripheral thyrotoxicosis in patients with MCT8 deficiency.
Source: fda.gov
MCT8 deficiency is also known as Allan-Herndon-Dudley syndrome.
Source: fda.gov
Symptoms of peripheral thyrotoxicosis include rapid heart rate, increased blood pressure, and adverse effects on metabolism.
Source: fda.gov
Emcitate is the first therapy approved by the FDA to treat symptoms of MCT8 deficiency.
Source: fda.gov
The therapy bypasses the broken transporter responsible for MCT8 deficiency to decrease elevated blood thyroid hormone levels.
Source: fda.gov
The active ingredient in Emcitate is tiratricol.
Source: fda.gov
Tiratricol can enter cells without relying on the MCT8 transporter.
Source: fda.gov
The effectiveness of Emcitate was evaluated in studies ranging from infants to adults.
Source: fda.gov
Studies showed Emcitate reduces excess thyroid hormone levels.
Source: fda.gov
Common side effects of Emcitate include diarrhea, vomiting, rash, and excessive sweating.
Source: fda.gov
Emcitate was granted Orphan Drug, Rare Pediatric Disease, Fast Track, and Breakthrough Therapy designations.
Source: fda.gov
The approval was granted to Egetis Therapeutics US Inc.
Marina Zemskova, Deputy Director of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research
"Until now, patients living with MCT8 deficiency and their families had no FDA-approved treatment option."

menu_bookBackground & Sources

Context and data our newsroom added to the originating report, with the primary source for each item shown below it.

The FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) granted to Egetis in connection with Emcitate’s approval could potentially be monetized, with the company planning to explore this in Q4 2026.
The FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval of Emcitate, which the company plans to monetize, potentially in the fourth quarter of 2026, subject to market conditions.
In 2025, the European Commission approved Emcitate® (tiratricol) as the first and only treatment for MCT8 deficiency in the EU, with a launch in Germany on May 1, 2025, setting a precedent for its subsequent FDA approval in the U.S.
The FDA's approval of Emcitate came after the completion of multiple clinical trials, including the ReTRIACt study, which demonstrated that tiratricol could significantly suppress serum T3 levels in patients with MCT8 deficiency, with effects sustained over up to 3.5 years.
Source: fda.gov
Egetis Therapeutics AB (parent company) received EU approval for Emcitate in February 2025, making it the first treatment for MCT8 deficiency in the EU, which served as a precedent for its subsequent FDA approval in the U.S.
The median life expectancy for patients with MCT8 deficiency is approximately 35 years, according to data provided by Egetis, highlighting the severity of the condition and the significance of the FDA’s approval of Emcitate.
Egetis Therapeutics has a history of receiving Orphan Drug, Fast Track, and Breakthrough Therapy designations for Emcitate in the U.S., reflecting its focus on addressing rare pediatric conditions with significant unmet medical needs.
Source: fda.gov
In the U.S., Emcitate is expected to be commercially available within eight to ten weeks post-approval, with Egetis launching its Egetis RareLink™ patient support program in partnership with PANTHERx® Rare to ensure access for patients and caregivers.
Egetis Therapeutics US Inc. was previously involved in the development of a drug for another rare condition, specifically a therapy for Resistance to Thyroid Hormone Beta (RTHβ), which received Orphan Drug Designation in both the EU and US.

forum Comments (0)

No comments yet. Be the first to comment.